Clinical Trial

Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia

Study acronym: MASTERKEY ASIA
Recruiting
View on ClinicalTrials.gov →
Summary
This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing. The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-01-19.
Trial Details
NCT Number NCT05217407
Lead Sponsor National Cancer Center, Japan
Conditions Rare Malignant Neoplasm
Enrollment 1,000 participants
Start Date 2021-11-30
Primary Completion 2027-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-22